US EditionCGM Usage Improves Glycemic, Psychosocial Outcomes for Type 1 Diabetes
Summary by drugtopics.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
All
Left
Center
Right
Senseonics lays out hopes for next-gen CGM commercial timelines
The components of the Eversense 365 CGM. [Image courtesy of Senseonics/Ascensia]Senseonics (NYSE:SENS) has offered some insight into its plans for its next-generation implantable continuous glucose monitors (CGMs). The maker of the Eversense 365 year-long implantable CGM hosted an analyst event during the American Diabetes Association’s 85th Scientific Sessions in Chicago this past weekend. At that event, the company touched on the commercial st…
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
